title: Ovalbumin lipid core peptide vaccines and their CD4(+) and CD8(+) T cell responses.
abstract: The lipid core peptide (LCP) system has successfully been used in development of peptide-based vaccines against cancer and infectious diseases (such as group A streptococcal infection). CD8(+) T cells are important targets for vaccines, however developing a vaccine that activates long-lasting immunity has proven challenging. The ability of LCP vaccines to activate antigen-specific CD8(+) and/or CD4(+) T cell responses was tested using compounds that contained two or four copies of OVA257-264 and/or OVA323-339 peptides conjugated to LCP, which are recognised by OTI (CD8(+) specific) and OTII (CD4(+) specific) T cells, respectively. The LCP-ovalbumin vaccines developed in this study were synthesised in 30% yields and showed no significant haemolytic effect on red blood cells (below 4% haemolysis when tested with compounds at up to 100μM concentrations). Promising in vivo data in mice suggested that this LCP-ovalbumin vaccine system could act as a novel and potent vehicle for the stimulation of robust antigen-specific CD8(+) T cell responses.
authors: School of Chemistry and Molecular Biosciences, The University of Queensland, Cooper Road, St. Lucia 4072, Queensland, Australia. Electronic address: p.simerska@uq.edu.au.
authors: Pavla
authors: P
authors: Simerska
authors: School of Chemistry and Molecular Biosciences, The University of Queensland, Cooper Road, St. Lucia 4072, Queensland, Australia.
authors: Tittaya
authors: T
authors: Suksamran
authors: School of Chemistry and Molecular Biosciences, The University of Queensland, Cooper Road, St. Lucia 4072, Queensland, Australia.
authors: Zyta Maria
authors: ZM
authors: Ziora
authors: Immunology and Infection Laboratory, Queensland Institute of Medical Research, Herston, QLD 4029, Australia.
authors: Fabian de Labastida
authors: Fde L
authors: Rivera
authors: Immunology and Infection Laboratory, Queensland Institute of Medical Research, Herston, QLD 4029, Australia.
authors: Christian
authors: C
authors: Engwerda
authors: School of Chemistry and Molecular Biosciences, The University of Queensland, Cooper Road, St. Lucia 4072, Queensland, Australia; School of Pharmacy, The University of Queensland, Pharmacy Australia Centre of Excellence, Cornwall Street, Woolloongabba, Queensland 4102, Australia. Electronic address: i.toth@uq.edu.au.
authors: Istvan
authors: I
authors: Toth
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D004912:Erythrocytes / Q000187:drug effects; D005260:Female; D006461:Hemolysis; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000737:chemistry / Q000276:immunology*; D022223:Vaccines, Subunit / Q000138:chemical synthesis / Q000276:immunology*
chemical_list: D022223:Vaccines, Subunit; D010047:Ovalbumin
keywords: CD4(+); CD8(+); Ovalbumin; Peptide synthesis; T cell; Vaccine development